ALGS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aligos Therapeutics Inc (ALGS) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has shown a recent price increase and hedge funds are buying, the company's financial performance is weak, with declining revenue and negative EPS. Additionally, no strong proprietary trading signals or significant positive catalysts are present to justify immediate action.
The MACD is positive and expanding, indicating a bullish momentum. However, the RSI is neutral at 63.484, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 7.538), suggesting limited immediate upside potential.
Hedge funds are significantly increasing their buying activity (+162.30% last quarter). Analyst Michael Yee from UBS has initiated a Buy rating with a $20 price target, indicating potential long-term upside.
The company's financials are weak, with a 41.61% YoY revenue drop and negative EPS (-3.04). There is no recent news or significant insider activity to drive short-term momentum. Additionally, no proprietary trading signals (AI Stock Picker or SwingMax) are present.
In Q3 2025, revenue dropped by 41.61% YoY to $741,000. Net income improved to -$31.54M (+63.75% YoY), but EPS declined slightly to -3.04 (-0.98% YoY). Gross margin remained at 100%, but overall financial performance is weak.
UBS analyst Michael Yee initiated coverage with a Buy rating and a $20 price target, highlighting potential long-term recovery in biotech fundamentals. However, the stock is not among the analyst's top picks in the sector.
